Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: Depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-αGal antibody

Xenotransplantation

Volumn 8, Issue 3, 2001, Pages 157-171

  Alwayn, Ian P J ^a   Xu, Yuanxin ^b   Basker, Murali ^a   Wu, Cecelia ^b   Buhler, Leo ^a   Lambrigts, Denis ^a   Treter, Sarah ^b   Harper, David ^b   Kitamura, Hiroshi ^a   Vitetta, Ellen S ^c   Abraham, Sonny ^b   Awwad, Michel ^b   White Scharf, Mary E ^b   Sachs, David H ^a   Thall, Aron ^b   Cooper, David K C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BioTransplant Inc   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anti Gal antibodies; Anti CD20 monoclonal antibody; Anti CD22 ricin A immunotoxin; Anti CD38 ricin A immunotoxin; B cells; Plasma cells; Primates; Xenotransplantation

Indexed keywords

ALPHA GALACTOSE ANTIBODY; ANTIBODY; CD20 ANTIGEN; CD22 ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY CD22; MONOCLONAL ANTIBODY CD38; RICIN A; RICIN ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BABOON; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG TARGETING; IMMUNOADSORPTION; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; WHOLE BODY RADIATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; B-LYMPHOCYTES; CELL ADHESION MOLECULES; DISACCHARIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; GRAFT REJECTION; HUMANS; IMMUNOTHERAPY; LECTINS; LYMPHOCYTE DEPLETION; MICE; PAPIO; PLASMA CELLS; RICIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 17844402696     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3089.2001.008003157.x     Document Type: Article

References (49)

1. The pig as a potential organ donor for man
2. The pig as a potential xenograft donor
3. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model
4. Barriers to xenotransplantation
5. The problem of anti-pig antibodies in pig-to-primate xenografting: Current and novel methods of depletion and/or suppression of production of anti-pig antibodies
6. Orthotopic heart transplantation in a transgenic pig-to-primate model
7. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors
8. Identification of carbohydrate structures that bind human anti-porcine antibodies: Implications for discordant xenografting in humans
9. Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-to-man organ xenotransplantation
10. Interaction of the natural anti-Gal antibody with (galactosyl epitopes: A major obstacle for xenotransplantation in humans
11. Evolutionary relationship between the natural anti-Gal antibody and the Gal 1→3Gal epitope in primates
12. A histopathologic grading system of hyperacute (humoral, antibody-mediated) cardiac xenograft and allograft rejection
13. Anti-(galactosyl (anti-Gal) antibody damage beyond hyperacute rejection
14. In vivo immunoadsorption of antipig antibodies in baboons using a specific Galα1-3Gal column
15. Depletion of anti-αGal1-3Gal antibody in baboons by specific immunoaffinity columns
16. Xenotransplantation of pig kidneys to nonhuman primates
17. Extracorporeal immunoadsorption of anti-pig antibody in pigs using αGal oligosaccharide immunoaffinity columns
18. Removal of anti-porcine natural antibodies from human and nonhuman primate plasma in vitro and in vivo by a Galα1-3Galβ1-4Glc-X immunoaffinity column
19. High-dose porcine hematopoietic cell transplantation combined with CD40L blockade in baboons prevents an induced anti-pig humoral response
20. Pharmacologic immunosuppressive therapy and extracorporeal immunoadsorption in the suppression of anti-αGal antibody in the baboon
21. Redesigning nature's poisons to create anti-tumor reagents
22. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin
23. Monoclonal antibody-based therapies of leukemia and lymphoma
24. Recombinant toxins for cancer treatment
25. Radiation-induced apoptosis: Relevance to radiotherapy
26. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages
27. Continuous infusion of the anti- CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study
28. Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue
29. Human CD38: A glycoprotein in search of a function
30. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
31. Characterization of a human B lymphocyte-specific antigen
32. Human blood dendritic cell-like B cells isolated by the 5G9 monoclonal antibody reactive with a novel 220-kDa antigen
33. Xenogeneic bone marrow transplantation: II. Porcine-specific growth factors enhance porcine bone marrow engraftment in an in vitro primate microenvironment
34. Generation of plasma cells from peripheral blood memory B cells: Synergistic effects of interleukin-10 and CD27/CD70 interaction
35. Prolongation of survival of guinea pig heart grafts in cobra venom factor-treated rats by splenectomy. No additional effect of cyclosporine
36. Splenectomy improves survival of hDAF transgenic pig kidneys in primates
37. Plasma perfusion by apheresis through a Gal immunoaffinity column successfully depletes anti-Gal antibody - Experience with 320 aphereses in baboons
38. Phase I immunotoxin trial in patients with B-cell lymphoma
39. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: A report of three cases
40. Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption
41. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin
42. Humoral immunity due to long-lived plasma cells
43. Lifetime of plasma cells in the bone marrow
44. The radiation resistance of long-lived lymphocytes and plasma cells in mouse and rat lymph nodes
45. Anti-Gal(alpha) 1-3Gal antibody response to porcine bone marrow in unmodified baboons and baboons conditioned for tolerance induction
46. Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail
47. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19-CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice
48. Treatment of plasma cell dyscrasias by antibody- mediated immunotherapy